那他珠单抗(Natalizumab)是治疗什么疾病的

Natalizumab is an integrin receptor antagonist. Please consult your physician for specific medication information.

What diseases does Natalizumab treat?

1. Multiple sclerosis (MS)

As a monotherapy, it is used to treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When initiating and continuing treatment with TYSABRI, physicians should evaluate whether the anticipated benefits are sufficient to offset such risks.

2. Crohn's disease (CD)

Natalizumab is indicated to induce and maintain clinical response and remission in adult patients with moderately to severely active Crohn's disease and evidence of inflammation. These patients have an inadequate response to or intolerance to traditional Crohn's disease therapies and tumor necrosis factor-alpha (TNF-alpha) inhibitors.

Important Restrictions:

For Crohn's disease, TYSABRI should not be used in combination with immunosuppressants or TNF-alpha inhibitors.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Natalizumab usage and dosage

1. Dosage

300 mg of the drug should be infused intravenously once every four weeks, and the infusion time should be more than one hour.

2. Medication precautions

It is prohibited to use intravenous injection or rapid injection.

Natalizumab solution must be infused within 48 hours after preparation.

3. Medication Observation

Patients need to be observed during all infusion processes. For the first 12 infusions, the patient needs to be observed for one hour after completion. If the patient has completed 12 infusions without experiencing hypersensitivity reactions, the observation time after the 13th and subsequent infusions can be adjusted based on clinical judgment.

4. Discontinuation treatment

For patients with Crohn's disease, if no therapeutic effect is shown after 12 weeks of induction therapy, or if long-term concomitant steroid drugs cannot be discontinued within six months of starting treatment, natalizumab treatment should be discontinued.

Precautions for Natalizumab

1. Herpes infection

There have been cases of fatal herpetic encephalitis and meningitis. Acute retinal necrosis can lead to blindness. If such an infection occurs, natalizumab needs to be discontinued immediately and targeted treatment must be initiated.

2. Hepatotoxicity

It may cause severe liver damage (including liver failure requiring liver transplantation). Natalizumab should be discontinued when evidence of liver damage appears.

3. Hypersensitivity reaction

Severe hypersensitivity reactions (such as anaphylactic shock) may occur. If symptoms occur, natalizumab must be permanently discontinued.

4. Immunosuppression/infection

Natalizumab may increase the risk of specific infections, and patients need to be monitored for signs of infection during treatment.

5. Hematological abnormalities

May cause thrombocytopenia. Patients need to be monitored for bleeding abnormalities and the drug should be discontinued if thrombocytopenia occurs. Neonates may develop thrombocytopenia and anemia, and neonates exposed to TYSABRI in utero should complete a complete blood count.

Adverse reactions of Natalizumab

1. Patients with multiple sclerosis

Headache, fatigue, joint pain, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, limb pain, abdominal discomfort, non-specific diarrhea and rash.

2. Crohn’s disease patients

Headache, upper respiratory tract infection, nausea and fatigue.

If you find any suspected adverse reactions of natalizumab, it is recommended to consult your doctor immediately.